Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:26:15.258Z.
Calculation as of: 2026-10-06T13:26:15.258Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Bright Minds Biosciences Inc.
Market Cap
$487.30M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$491.55M
EV/EBITDA Ratio
N/A
TTM Avg
74.72x
3Y Avg
37.71x
5Y Avg
26.88x
Market Cap
$478.54M
EV/EBITDA Ratio
N/A
TTM Avg
5.88x
3Y Avg
17.52x
5Y Avg
17.52x
Market Cap
$471.57M
EV/EBITDA Ratio
8036.17x
TTM Avg
8683.24x
3Y Avg
8683.24x
5Y Avg
8683.24x
Market Cap
$517.73M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $487.30M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | N/A | 74.72x | 37.71x | 26.88x |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 5.88x | 17.52x | 17.52x |
| Cerus Corporation (CERS)vs › | $471.57M | 8036.17x | 8683.24x | 8683.24x | 8683.24x |
| NRC Health (NRC)vs › | $468.31M | 23.75x | 16.39x | 15.03x | 16.69x |
| Kamada Ltd. (KMDA)vs › | $461.55M | 10.29x | 9.91x | 9.78x | 16.95x |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
